

Permit No MITA (P) 265/09/00
 PP (S) No 580/12/95
 ISSN 0037 - 5675

JOURNAL OF THE SINGAPORE
 MEDICAL ASSOCIATION

Editor

Dr C Rajasoorya

Deputy Editor

Dr Sonny Wang Yee Tang

Corresponding Editors

Prof Azrul Azwar (Indonesia)
 Prof Myo Myint (Myanmar)
 Prof Neil Pride (UK)
 Prof Tan Chong Tin (Malaysia)
 Prof Victor Yu (Australia)
 Prof Teh Bin Tean (USA)

Editorial Board

A/Prof Ho Nai Kiong
 Dr Kenneth Lyen
 Prof Kua Ee Heok
 Dr Denis Nyam
 Dr Wilfred C G Peh
 A/Prof Luke Tan Kim Siang

Ex-Officio

A/Prof Goh Lee Gan
 Dr Yue Wai Mun

Editorial Assistants

Chua Gek Eng
 Dr Tham Wai Fong, Eileen

Editorial Address

Dr C Rajasoorya, Editor
 Singapore Medical Journal
 Singapore Medical Association
 2 College Road
 Singapore 169850

Helicobacter pylori Infection and its Treatment in Singapore

K G Yeoh

Helicobacter pylori infection is now recognised to be the most important aetiology for peptic ulcer disease and a significant risk factor for gastric cancer. Half the world's population is infected and it is a global health problem. The infection is common in Singapore and its epidemiology has been well described. The prevalence of infection increases with age in all races, from 3% in children below 5 years to 71% in adults above 65 years⁽¹⁾. The pattern is similar to that in developed countries. However there are marked differences among the three major ethnic groups⁽²⁾. The prevalence of *H pylori* infection is highest in Indians, followed by Chinese and lowest in Malays. For instance in the age group 51-60 years, the prevalence of (*H pylori*) antibodies is 70% in Indians, 43% in Chinese and 35.7% in Malays ($p < 0.01$). The corresponding odds ratio for infection in Indians and Chinese are 3.0 (1.5 to 5.9) and 1.5 (0.7-2.9) respectively, compared to Malays.

The majority of people with *H pylori* infection do not develop clinical disease or symptoms, and the lifetime risk of developing ulcer disease is estimated at 10-15% while that of gastric cancer is 1-2%. *Who should be treated?* Consensus guidelines^(3,4) have been developed to provide guidance on indications for therapy (Table I) and treatment regimes. The strongest evidence for the treatment of *H pylori* is in association with peptic ulcer disease. Eradication has been shown to heal ulcers, dramatically reduce recurrence and produce long term remission⁽⁵⁾. It is also cost-effective because it prevents recurrence of ulcer disease and its complications. Whether the infection should be treated in patients with non-ulcer dyspepsia is still a matter of controversy. *What is the best treatment?* Evidence from randomised controlled trials show that the best results are obtained with a

Table 1. Recommendations for treatment of *H pylori* infection:

Treatment of *H pylori* infection is recommended when associated with the following (modified from reference 4):

Indication	Level of evidence
Duodenal ulcer	Randomised controlled trials
Gastric ulcer	Randomised controlled trials
Complicated ulcer (bleeding or perforation)	Randomised controlled trials
NSAID* therapy, past history of ulcer	Expert Committee report
NSAID therapy, in patients with dyspepsia	Expert Committee recommendation
Following resection of early gastric cancer	Expert Committee report
Low-grade MALT** lymphoma	Expert Committee report
Non-ulcer dyspepsia, case-by-case basis	Expert Committee report

* Non-steroidal anti-inflammatory drug; ** Mucosa-associated lymphoid tissue



Cover Picture:
 Initial cystography
 performed through
 the indwelling
 suprapubic catheter.
 (Refer to page 511)

**Department of
 Medicine
 National University
 of Singapore**

K G Yeoh
 Associate Professor &
 Consultant

triple therapy regimen comprising a proton-pump inhibitor and two antibiotics (clarithromycin and either amoxicillin or metronidazole), which give eradication rates exceeding 90% on per-protocol analysis⁽⁶⁾. There is a relatively high rate of primary metronidazole resistance in *H pylori* strains in this region and therefore the combination of clarithromycin and amoxicillin may be preferred. In this issue, Fock and co-authors report the results of an earlier randomised trial on dual therapy comparing amoxicillin versus clarithromycin in combination with omeprazole⁽⁷⁾. This study showed the combination of omeprazole and clarithromycin produced an eradication rate of 75% and was well tolerated. It is now recognised that dual therapy is less effective than triple therapy, and as a result the latter is the treatment of choice.

There are peculiar features of *H pylori* infection in Singapore and some differences compared to western populations. There appears to be a lower prevalence of *H pylori* among local peptic ulcer patients compared to western figures. The study by Vu in this issue diagnosed *H pylori* in 85% of duodenal ulcer patients and 68% of gastric ulcer patients presenting to a local hospital endoscopy unit⁽⁸⁾, which is lower than the corresponding prevalence of 95% among Caucasian patients with duodenal ulcer⁽⁹⁾. The author was careful in documenting the use of non-steroidal anti-inflammatory drugs (NSAIDs), although since patient particulars were retrieved from case files it is possible that this was under-recorded. An earlier study by Kang *et al* in 1990 showed similar results⁽¹⁰⁾. Besides *H pylori*, the next most important cause of ulcer disease are NSAIDs, however even after exclusion of the latter, Vu found no obvious cause in 13% and 28% of duodenal and gastric ulcer disease respectively. The author was also careful in screening out possible confounding factors such as the use of recent antibiotics and proton pump inhibitors which could potentially result in false negative *H pylori* status. If this suspicion of a lower than expected prevalence of *H pylori* in local peptic ulcer patients is substantiated, it suggests other factors contributing to the development of ulcer disease that have not been elucidated. Yet another significant difference is the high prevalence of *cagA*-positive *H pylori* strains (73 to 89% in Singapore)^(11,12) compared to western figures (60%). *cagA* is a marker for a complex of many genes, which some workers have linked with more severe disease outcomes in western studies. It is associated with increased mucosal IL-8 and inflammation, however it does not seem to be predictive of disease outcomes in our population^(11,12).

Interesting questions remain to be answered. Why do only a minority of *H pylori*-infected people develop disease? Possibilities include differences in bacterial strains and virulence genes, host factors or host-bacterial interaction. Our group found no difference in the prevalence of putative bacterial virulence genes such as *cagA*, *vacA* and *iceA* in patients with peptic ulcer compared to those with non-ulcer dyspepsia^(11,13). Furthermore, the ethnic prevalence of *H pylori* infection does not adequately explain the differences in ulcer frequency in the three races in Singapore. Recent evidence suggests that host factors such as Lewis blood group antigens, which are also expressed by *H pylori*, may be important in determining the development of peptic ulcer in people with *H pylori* infection⁽¹³⁾. Our group's hypothesis is that disease outcomes of *H pylori* infection are due to host-bacterial interaction rather than specific bacterial virulence factors *per se*.

The remarkable progress over the last decade in clarifying the role of *H pylori* in duodenal and gastric ulcer disease has led to simple and effective treatment which has almost eliminated complicated ulcer disease. This triumph of modern medicine is a model of how an understanding of

Eradication has been shown to heal ulcers, dramatically reduce recurrence and produce long term remission.

Publisher

Singapore Medical Journal
Level 2, Alumni Medical Centre
2 College Road
Singapore 169850
Tel: 223-1264
Fax: 224-7827
URL <http://www.sma.org.sg>

Design and Advertising

Lancer Communications
5 Kampong Bahru
Singapore 169341
Tel: 324 4337
Fax: 324 4661
Email: maxlancer@pacific.net.sg

For advertising placement, call

- Hwee Ping at 223-1264 for classified / professional advertisement announcements
- Charlie Teo at 324-4337 for other advertisements

Printed by Entraco Printing Pte Ltd

pathophysiology is translated into cure of disease. The “classical ulcer sufferer” described in the textbooks need suffer no longer after a one week course of triple therapy. However as in many other fields, the challenge now is to work out an understanding of the molecular mechanisms. Why does *H pylori* cause disease in only a minority of people? What is its role in gastric carcinogenesis? Can the progression to gastric cancer be reversed by its eradication? The final goal would be a therapeutic and prophylactic vaccine to eliminate the infection, without problems associated with antibiotic use and drug resistance. **SMB**

REFERENCES

1. Seroprevalence of *H pylori* infection in Singapore. *Epidemiol News Bull* 1996; 22:31-2.
2. Kang JY, Yeoh KG, Ho KY, Guan R, Lim TP, Quak SH, Wee A, Teo D, Ong YW. Racial differences in *Helicobacter pylori* seroprevalence in Singapore: correlation with differences in peptic ulcer frequency. *J Gastroenterol Hepatol* 1997; 12:655-9.
3. Lam SK, Talley NJ. Report of the 1997 Asian Pacific Consensus Conference on the management of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 1998; 13:1-12.
4. Management of *Helicobacter pylori* infection. Clinical Practice Guidelines, Ministry of Health, Singapore, October 1998.
5. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with *Helicobacter pylori* eradication: seven-year follow-up. *Lancet* 1994; 343:258-9.
6. Fock KM, Chelvam P, Lim SG and the South-East Asia Multicentre Study Group. Triple therapy in the eradication of *Helicobacter pylori* in patients with duodenal ulcer: results of a multi-centre study in South-East Asia. *Aliment Pharmacol Ther* 2000; 14:225-31.
7. Fock KM, Ng HS, Ng TM, Law NM, Lim CC. A randomised trial of amoxicillin versus clarithromycin in combination with omeprazole for eradication of *Helicobacter pylori* infection in Singapore. *Singapore Med J* 2000; 41(10):482-4.
8. Vu C, Ng Y Y. Prevalence of *Helicobacter pylori* in peptic ulcer disease in a Singapore Hospital. *Singapore Med J* 2000; 41(10):478-81.
9. Kuipers EJ, Thijs JC, Festen HPM. The prevalence of *Helicobacter pylori* in peptic ulcer disease. *Aliment Pharmacol Ther* 1995; 9 Suppl 2:59-69.
10. Kang JY, Wee A, Math MV, Guan R, Tay HH, Yap I, et al. *Helicobacter pylori* and gastritis in patients with peptic ulcer and non-ulcer dyspepsia: ethnic differences in Singapore. *Gut* 1990; 31(8):850-3.
11. Hua J, Zheng P, Yeoh KG, Ho B. The enigmatic prevalence of *cagA*-positive *Helicobacter pylori* in Singapore. *Microbios* 2000 (in press).
12. Ng TM, Fock KM, Ng HC, Ho B. The seroprevalence of IgG antibodies to *Helicobacter pylori cagA* protein in patients with peptic ulcer disease, gastric cancer and non-ulcer dyspepsia in Singapore. *J Gastroenterol Hepatol* 1995; 10 (Suppl 3):A81.
13. Zheng P, Hua J, Yeoh KG, Ho B. Association of peptic ulcer with increased expression of Lewis antigens but not *cagA*, *iceA* and *vacA* in *Helicobacter pylori* in an Asian population. *Gut* 2000; 47:18-22.

The Singapore Medical Journal is published monthly by the Singapore Medical Association. All articles published, including editorials, letters & book reviews represent the opinion of the authors and do not reflect the official policy of the SMA or Institution with which the authors is affiliated unless this is clearly specified. The Publisher cannot accept responsibility for the correctness or accuracy of the advertisers' text and/or claim or any opinion expressed. The appearance of advertisements in the Journal does not necessarily constitute an approval or endorsement by the SMA of the product or service advertised. The contents of this publication are not to be quoted in the press without permission of the Editor.

ERRATUM

In the article “Paediatric One Lung Anaesthesia by Selective Bronchial Intubation” published in Vol 41 issue 8 August 2000, Table 1 should read “ $\text{pH at PCO}_2 \text{ of } 40 \text{ mmHg} = \text{measured pH} + (\text{measured PCO}_2 - 40) \text{ mmHg} \times 0.008$ ”.

H. pylori infection is common in Singapore and its prevalence increases with age. Most people with H. pylori infection do not develop clinical disease or symptoms, but there is a risk of developing ulcer disease and gastric cancer. These guidelines provide useful recommendations on who should be tested and treated for H. pylori infection, and includes discussion on drug regimens for treatment. I hope you find the guidelines useful in your own practice. After treatment of H. pylori infection, cure of infection should be demonstrated in patients treated either for gastric ulcer (GU) or complicated duodenal ulcer (DU). In patients treated for GU, repeat endoscopy and biopsy should be undertaken to exclude malignancy; additional biopsies may be taken for determination of H. pylori status. Read about h. pylori and its strong correlation to stomach cancer from the Cleveland Clinic, including commentary from the Cleveland Clinic. Helicobacter Pylori and Stomach Cancer. Helicobacter pylori (H. pylori), a type of bacteria, is recognized as a primary cause of peptic ulcers and their recurrence. Now evidence has been found linking H. pylori infection as a risk factor for stomach cancer. Appointments 216.444.7000. Appointments & Locations. Contact Us. What is H. pylori infection? A bacterial infection called Helicobacter pylori (H. pylori) is now recognized as a primary cause of peptic ulcers and their recurrence. Evidence has been found linking the changes caused by H. pylori infection in the stomach lining as a strong Helicobacter Pylori (H. pylori) is a type of bacteria. This spiral shaped bacterium can cause chronic inflammation in the inner lining of the stomach and in duodenum. These bacteria enter your body and live in your digestive tract. Over time, they can cause sores (ulcers) in the lining of your stomach or the upper part of your small intestine. In some people, this infection can lead to stomach cancer. Is Helicobacter Pylori infection common? Yes, about two-thirds of the world's population has it in their bodies. Normally, it doesn't cause ulcers or any other symptoms. PDF | Background Helicobacter pylori (H. pylori) infection is currently considered as an infectious disease irrespective of symptoms and stage of | Find, read and cite all the research you need on ResearchGate. Conclusions: The prevalence of H. pylori infection and its infection rates in related gastrointestinal diseases were significantly different among Southeast Asian countries. The prognosis of patients with GC in the region was very poor. Country Cambodia Indonesia Laos Malaysia Myanmar Philippines Singapore Thailand Vietnam. Most common test for H. pylori diagnosis before treatment. Serology + - +. Stool Ag test +